Cryoport, Inc., a cryogenic logistics company for the life sciences, will support Gradalis‘ clinical trials evaluating its investigational Vigil Engineered Autologous Tumor Cell (EATC) immunotherapy technology for use in cancer treatments. Cryoport is currently supporting Gradalis’ Phase II/III trial for high risk stage III/IV ovarian cancer patients, its Phase IIb trial for Ewing’s sarcoma, as well as the pilot combination studies with PD-1/PD-L1 inhibitors, all of which use the Vigil bi-shRNA furin and GMCSF.

Cryoport’s global distribution network will provide cryogenic logistics support for multiple clinical sites throughout the U.S. Cryoport’s cryogenic cold chain logistics solutions will extend access to patients currently enrolled in the trials.

Sunil Joshi, president and chief executive officer of Gradalis said, “We rely on Cryoport’s advanced cryogenic logistics solutions to maintain the integrity of our clinical trial work as the therapies are transported between Gradalis’ manufacturing and various clinical sites. We are at a critical stage of our development and we need to ensure proper access for our clinical trial participants. With the advancements we have made thus far, we look forward to further developing our proprietary platform for additional applications. Cryoport, as with all of our partners, will play a critical supporting role in the success of our clinical programs.”

Jerrell Shelton, chief executive officer of Cryoport, said, “We are honored to support Gradalis in its efforts to develop cutting edge immunotherapy treatments for ovarian cancer, Ewing’s sarcoma and other cancers. Gradalis’ technology has the potential to address this significant unmet medical need in this patient population. We look forward to providing Gradalis with our advanced and validated cryogenic logistics solutions including 24/7/365 support to help move it closer to managing these life-threating diseases.”